Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Association between plasma activities of semicarbazide-sensitive amine oxidase and angiotensin-converting enzyme in patients with type 1 diabetes mellitus

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Experimental non-severe hypoglycaemia substantially impairs cognitive function in type 2 diabetes: a randomised crossover trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Are early dumping and postprandial hypoglycemia after Roux-en-Y gastric bypass related events?

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  3. Cell populations and molecular biomarkers in blood and urine characterise nephropathy in type 1 diabetes

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  1. Liraglutide preserved insulin secretion in adults with newly diagnosed type 1 diabetes: the NewLira trial

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  2. Asymptomatic hypoglycaemia in Type 1 diabetes: incidence and risk factors

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

AIMS/HYPOTHESIS: Plasma semicarbazide-sensitive amine oxidase (SSAO) is elevated in patients with type 1 and type 2 diabetes and has been implicated in the pathophysiology of diabetic late complications. The regulation of SSAO production remains unknown. We studied correlations between plasma SSAO activity and parameters associated with diabetic late complications.

METHODS: Plasma SSAO was measured in a well-characterised group of 287 patients with type 1 diabetes. Standard statistical methods were used to investigate correlations with clinical parameters and components of the renin-angiotensin system.

RESULTS: Overall, plasma SSAO was elevated, at 693+/-196 mU/l (mean+/-SD; normal controls 352+/-102 mU/l). Plasma SSAO was higher in the group with late complications or hypertension, and in patients treated with ACE-inhibitors. In univariate analysis a significant positive correlation (p<0.001, r=0.27) was found between plasma SSAO and serum ACE activity in patients untreated with ACE inhibitors or angiotensin II receptor antagonists (n=221), but plasma SSAO did not differ by ACE I/D genotype. Plasma SSAO correlated positively with duration of diabetes, HbA(1)c and plasma renin, and negatively with plasma angiotensinogen and body mass index. A multiple regression analysis including these variables resulted in serum ACE activity (p<0.001), ACE genotype (negatively, p<0.001) and HbA(1)c (p=0.023) as explaining variables.

CONCLUSIONS/INTERPRETATION: Results suggest that a common factor is involved in the regulation of both plasma SSAO and serum ACE, which is different from the genetic determination of ACE activity.

Original languageEnglish
JournalDiabetologia
Volume48
Issue number5
Pages (from-to)1002-7
Number of pages6
ISSN0012-186X
DOIs
Publication statusPublished - May 2005

    Research areas

  • Amine Oxidase (Copper-Containing), Angiotensin-Converting Enzyme Inhibitors, Body Mass Index, Diabetes Mellitus, Type 1, Diabetic Angiopathies, Diabetic Foot, Diabetic Nephropathies, Diabetic Neuropathies, Diabetic Retinopathy, Hemoglobin A, Glycosylated, Humans, Peptidyl-Dipeptidase A, Journal Article, Research Support, Non-U.S. Gov't

ID: 51548619